Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK technology. This platform, which can target multiple antigens simultaneously, now extends its potential applications beyond oncology to various autoimmune diseases.
February 26, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics' expansion of its exclusive license for SNAP-CAR T and NK technology to cover autoimmune diseases could significantly enhance its market potential.
By broadening the application of its SNAP-CAR T and NK technology to include autoimmune diseases, Coeptis Therapeutics not only diversifies its potential product pipeline but also opens up new markets beyond oncology. This strategic move could attract investor interest and potentially lead to an increase in the company's stock price in the short term, given the high interest in innovative treatments in both oncology and autoimmune diseases.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90